GlassScriptPhysician profile
Matthew Scales
NPI 1699425553
$1,768.99
in general payments reported to CMS, 2019-2025
14 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $135 · 2024: $999 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $295.68 | 2024 | Auryon Laser System 100-120 Vac |
| Inari Medical, INC. | $286.81 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Scientific Affairs, LLC | $248.87 | 2024-2025 | Tremfya |
| Abbvie INC. | $186.67 | 2024-2025 | |
| Insmed, INC. | $136.92 | 2022 | |
| Amgen INC. | $132.49 | 2025 | Evenity |
| Genzyme Corporation | $119.01 | 2025 | |
| Lucid Diagnostics INC. | $100.43 | 2023 | |
| Shockwave Medical, INC | $73.84 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.47 | 2023-2024 | Ofev |
| Ucb, INC. | $50.08 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $46.16 | 2024 | Tremfya |
| Stryker Corporation | $20.45 | 2025 | Flowtriever |
| Idorsia Pharmaceuticals US INC | $14.11 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Scales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.